Does the media refer more to INSP or BWAY?

In the previous week, Inspire Medical Systems had 3 more articles in the media than Brainsway. MarketBeat recorded 9 mentions for Inspire Medical Systems and 6 mentions for Brainsway. Inspire Medical Systems' average media sentiment score of 1.24 beat Brainsway's score of 0.61 indicating that Inspire Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspire Medical Systems 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, LMAT or BWAY?

LeMaitre Vascular has higher revenue and earnings than Brainsway. Brainsway is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LeMaitre Vascular $262.43M 7.03 $57.73M $2.85 28.31 Brainsway $52.22M 9.07 $7.57M $0.44 26.75

Does the media favor LMAT or BWAY?

In the previous week, Brainsway had 3 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for Brainsway and 3 mentions for LeMaitre Vascular. Brainsway's average media sentiment score of 0.61 beat LeMaitre Vascular's score of 0.00 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainsway 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ESTA or BWAY?

In the previous week, Establishment Labs had 1 more articles in the media than Brainsway. MarketBeat recorded 7 mentions for Establishment Labs and 6 mentions for Brainsway. Establishment Labs' average media sentiment score of 0.87 beat Brainsway's score of 0.61 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, BWAY or NVCR?

Brainsway has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 9.07 $7.57M $0.44 26.75 NovoCure $655.35M 2.59 -$136.23M -$1.30 N/A

Is BWAY or NVCR more profitable?

Brainsway has a net margin of 15.65% compared to NovoCure's net margin of -21.25%. Brainsway's return on equity of 12.74% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets Brainsway 15.65% 12.74% 8.17% NovoCure -21.25% -44.00% -15.85%

Does the media prefer BWAY or NVCR?

In the previous week, Brainsway had 3 more articles in the media than NovoCure. MarketBeat recorded 6 mentions for Brainsway and 3 mentions for NovoCure. NovoCure's average media sentiment score of 0.86 beat Brainsway's score of 0.61 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainsway 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KMTS or BWAY?

In the previous week, Brainsway had 4 more articles in the media than Kestra Medical Technologies. MarketBeat recorded 6 mentions for Brainsway and 2 mentions for Kestra Medical Technologies. Brainsway's average media sentiment score of 0.61 beat Kestra Medical Technologies' score of 0.54 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kestra Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Brainsway (BWAY) Competitors

$11.77 +0.30 (+2.62%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$11.74 -0.03 (-0.21%)

As of 10/9/2026 07:30 PM Eastern

Compare

BWAY vs. INSP, LMAT, ESTA, NVCR, and KMTS

Should you buy Brainsway stock or one of its competitors? Brainsway's main competitors and comparable companies include Inspire Medical Systems (INSP), LeMaitre Vascular (LMAT), Establishment Labs (ESTA), NovoCure (NVCR), and Kestra Medical Technologies (KMTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Brainsway compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Inspire Medical Systems has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

Inspire Medical Systems presently has a consensus target price of $67.29, indicating a potential downside of 2.33%. Brainsway has a consensus target price of $18.20, indicating a potential upside of 54.63%. Given Brainsway's stronger consensus rating and higher possible upside, analysts plainly believe Brainsway is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	4 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.05
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

94.9% of Inspire Medical Systems shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 2.2% of Inspire Medical Systems shares are held by company insiders. Comparatively, 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Inspire Medical Systems had 3 more articles in the media than Brainsway. MarketBeat recorded 9 mentions for Inspire Medical Systems and 6 mentions for Brainsway. Inspire Medical Systems' average media sentiment score of 1.24 beat Brainsway's score of 0.61 indicating that Inspire Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspire Medical Systems	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainsway has a net margin of 15.65% compared to Inspire Medical Systems' net margin of 15.03%. Brainsway's return on equity of 12.74% beat Inspire Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	15.03%	8.64%	7.45%
Brainsway	15.65%	12.74%	8.17%

Inspire Medical Systems has higher revenue and earnings than Brainsway. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	2.18	$145.42M	$4.62	14.91
Brainsway	$52.22M	9.07	$7.57M	$0.44	26.75

Summary

Brainsway beats Inspire Medical Systems on 10 of the 17 factors compared between the two stocks.

How does Brainsway compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

In the previous week, Brainsway had 3 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for Brainsway and 3 mentions for LeMaitre Vascular. Brainsway's average media sentiment score of 0.61 beat LeMaitre Vascular's score of 0.00 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

LeMaitre Vascular has higher revenue and earnings than Brainsway. Brainsway is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$262.43M	7.03	$57.73M	$2.85	28.31
Brainsway	$52.22M	9.07	$7.57M	$0.44	26.75

LeMaitre Vascular presently has a consensus price target of $110.60, suggesting a potential upside of 37.07%. Brainsway has a consensus price target of $18.20, suggesting a potential upside of 54.63%. Given Brainsway's stronger consensus rating and higher probable upside, analysts plainly believe Brainsway is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

LeMaitre Vascular has a net margin of 25.02% compared to Brainsway's net margin of 15.65%. LeMaitre Vascular's return on equity of 15.63% beat Brainsway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	25.02%	15.63%	10.06%
Brainsway	15.65%	12.74%	8.17%

84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 19.0% of Brainsway shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

LeMaitre Vascular and Brainsway tied by winning 8 of the 16 factors compared between the two stocks.

How does Brainsway compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Establishment Labs currently has a consensus price target of $100.25, indicating a potential upside of 62.56%. Brainsway has a consensus price target of $18.20, indicating a potential upside of 54.63%. Given Establishment Labs' stronger consensus rating and higher probable upside, equities analysts plainly believe Establishment Labs is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Brainsway has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	8.71	-$51.06M	-$1.31	N/A
Brainsway	$52.22M	9.07	$7.57M	$0.44	26.75

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by insiders. Comparatively, 19.0% of Brainsway shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Establishment Labs had 1 more articles in the media than Brainsway. MarketBeat recorded 7 mentions for Establishment Labs and 6 mentions for Brainsway. Establishment Labs' average media sentiment score of 0.87 beat Brainsway's score of 0.61 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainsway has a net margin of 15.65% compared to Establishment Labs' net margin of -15.82%. Brainsway's return on equity of 12.74% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-15.82%	-196.69%	-10.73%
Brainsway	15.65%	12.74%	8.17%

Establishment Labs has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

Summary

Brainsway beats Establishment Labs on 9 of the 16 factors compared between the two stocks.

How does Brainsway compare to NovoCure?

Brainsway (NASDAQ:BWAY) and NovoCure (NASDAQ:NVCR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Brainsway has a net margin of 15.65% compared to NovoCure's net margin of -21.25%. Brainsway's return on equity of 12.74% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.65%	12.74%	8.17%
NovoCure	-21.25%	-44.00%	-15.85%

Brainsway has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	9.07	$7.57M	$0.44	26.75
NovoCure	$655.35M	2.59	-$136.23M	-$1.30	N/A

Brainsway has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

In the previous week, Brainsway had 3 more articles in the media than NovoCure. MarketBeat recorded 6 mentions for Brainsway and 3 mentions for NovoCure. NovoCure's average media sentiment score of 0.86 beat Brainsway's score of 0.61 indicating that NovoCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainsway presently has a consensus target price of $18.20, suggesting a potential upside of 54.63%. NovoCure has a consensus target price of $21.20, suggesting a potential upside of 45.40%. Given Brainsway's stronger consensus rating and higher probable upside, equities analysts clearly believe Brainsway is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

30.1% of Brainsway shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 19.0% of Brainsway shares are held by company insiders. Comparatively, 6.6% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Brainsway beats NovoCure on 13 of the 16 factors compared between the two stocks.

How does Brainsway compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

30.1% of Brainsway shares are owned by institutional investors. 5.3% of Kestra Medical Technologies shares are owned by company insiders. Comparatively, 19.0% of Brainsway shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Brainsway has lower revenue, but higher earnings than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$106.73M	15.06	-$131.61M	-$2.67	N/A
Brainsway	$52.22M	9.07	$7.57M	$0.44	26.75

Kestra Medical Technologies currently has a consensus target price of $28.38, suggesting a potential upside of 5.17%. Brainsway has a consensus target price of $18.20, suggesting a potential upside of 54.63%. Given Brainsway's stronger consensus rating and higher possible upside, analysts clearly believe Brainsway is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Brainsway has a net margin of 15.65% compared to Kestra Medical Technologies' net margin of -140.43%. Brainsway's return on equity of 12.74% beat Kestra Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-140.43%	-63.83%	-44.76%
Brainsway	15.65%	12.74%	8.17%

Kestra Medical Technologies has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

In the previous week, Brainsway had 4 more articles in the media than Kestra Medical Technologies. MarketBeat recorded 6 mentions for Brainsway and 2 mentions for Kestra Medical Technologies. Brainsway's average media sentiment score of 0.61 beat Kestra Medical Technologies' score of 0.54 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kestra Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Brainsway beats Kestra Medical Technologies on 14 of the 16 factors compared between the two stocks.

Get Brainsway News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BWAY vs. The Competition

Export

Metric	Brainsway	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$461.61M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	26.75	25.57	274.15	26.16
Price / Sales	9.07	83.25	635.98	113.06
Price / Cash	48.99	31.87	76.38	53.09
Price / Book	6.29	5.93	11.21	6.34
Net Income	$7.57M	$146.18M	$3.50B	$381.90M
7 Day Performance	-5.84%	-0.38%	-0.90%	-1.41%
1 Month Performance	-15.38%	-2.02%	-4.44%	-3.48%
1 Year Performance	56.10%	5.08%	6.96%	1.16%

Brainsway Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BWAY Brainsway	4.5893 of 5 stars	$11.77 +2.6%	$18.20 +54.6%	+51.3%	$461.61M	$52.22M	26.75	129
INSP Inspire Medical Systems	2.8165 of 5 stars	$70.78 +1.1%	$66.50 -6.0%	-14.1%	$2.05B	$911.98M	15.32	1,333	Positive News Analyst Upgrade
LMAT LeMaitre Vascular	4.0354 of 5 stars	$82.05 -0.4%	$110.60 +34.8%	-7.6%	$1.88B	$249.60M	28.87	655	Analyst Upgrade
ESTA Establishment Labs	3.3316 of 5 stars	$62.72 -4.0%	$100.25 +59.8%	+53.7%	$1.88B	$211.08M	N/A	1,004
NVCR NovoCure	3.0353 of 5 stars	$15.93 +0.7%	$21.20 +33.0%	+1.7%	$1.86B	$655.35M	N/A	1,605	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BWAY) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainsway (BWAY) Competitors

BWAY vs. INSP, LMAT, ESTA, NVCR, and KMTS

How does Brainsway compare to Inspire Medical Systems?

Summary

How does Brainsway compare to LeMaitre Vascular?

Summary

How does Brainsway compare to Establishment Labs?

Summary

How does Brainsway compare to NovoCure?

Summary

How does Brainsway compare to Kestra Medical Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainsway (BWAY) Competitors

BWAY vs. INSP, LMAT, ESTA, NVCR, and KMTS

How does Brainsway compare to Inspire Medical Systems?

Which has more volatility & risk, INSP or BWAY?

Do analysts recommend INSP or BWAY?

Do institutionals & insiders have more ownership in INSP or BWAY?

Does the media refer more to INSP or BWAY?

Is INSP or BWAY more profitable?

Which has higher valuation and earnings, INSP or BWAY?

Summary

How does Brainsway compare to LeMaitre Vascular?

Does the media favor LMAT or BWAY?

Which has more risk and volatility, LMAT or BWAY?

Which has better earnings and valuation, LMAT or BWAY?

Do analysts rate LMAT or BWAY?

Is LMAT or BWAY more profitable?

Do institutionals & insiders hold more shares of LMAT or BWAY?

Summary

How does Brainsway compare to Establishment Labs?

Do analysts recommend ESTA or BWAY?

Which has better earnings and valuation, ESTA or BWAY?

Do insiders and institutionals have more ownership in ESTA or BWAY?

Does the media prefer ESTA or BWAY?

Is ESTA or BWAY more profitable?

Which has more risk & volatility, ESTA or BWAY?

Summary

How does Brainsway compare to NovoCure?

Is BWAY or NVCR more profitable?

Which has stronger earnings & valuation, BWAY or NVCR?

Which has more volatility and risk, BWAY or NVCR?

Does the media prefer BWAY or NVCR?

Do analysts recommend BWAY or NVCR?

Do institutionals & insiders hold more shares of BWAY or NVCR?

Summary

How does Brainsway compare to Kestra Medical Technologies?

Do insiders & institutionals hold more shares of KMTS or BWAY?

Which has better valuation and earnings, KMTS or BWAY?

Do analysts recommend KMTS or BWAY?

Is KMTS or BWAY more profitable?

Which has more risk & volatility, KMTS or BWAY?

Does the media refer more to KMTS or BWAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools